[1] Wang N, Ma Y, Liu YH, et al. Risk of Treatment Failure in Patients with Drug-susceptible Pulmonary Tuberculosis in China. Biomed Environ Sci, 2016; 29, 612-7. https://www.researchgate.net/publication/308548293_Risk_of_Treatment_Failure_in_Patients_with_Drug-susceptible_Pulmonary_Tuberculosis_in_China
[2] World Health Organiztion. Global Tuberculosis Report 2016. WHO, Geneva, Switzerland, 2016.
[3] Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf, 2006; 5, 231-49. doi:  10.1517/14740338.5.2.231
[4] Edwards IR, Aronson JK. Adverse drug reactions:definitions, diagnosis, and management. Lancet, 2000; 356, 1255-9. doi:  10.1016/S0140-6736(00)02799-9
[5] Torun T, Gungor G, Ozmen I, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2005; 9, 1373-7. https://www.researchgate.net/publication/7306589_Side_effects_associated_with_the_treatment_of_multidrug-resistant_tuberculosis
[6] Marra F, Marra CA, Bruchet N, et al. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. Int J Tuberc Lung Dis, 2007; 11, 868-75. http://d.scholar.cnki.net/detail/SJPD2059_U/SJPD12102203503185
[7] Shin SS, Pasechnikov AD, Gelmanova IY, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis, 2007; 11, 1314-20. http://d.scholar.cnki.net/detail/SJPD2059_U/SJPD12102203695650
[8] Romanillos T, Casagran A, Barbeta E, et al. Pulmonary tuberculosis:effectiveness and tolerance of a 6-month treatment schedule using 4 drugs. Rev Clin Esp, 1990; 186, 116-8. https://www.researchgate.net/publication/20800439_Pulmonary_tuberculosis_effectiveness_and_tolerance_of_a_6-month_treatment_schedule_using_4_drugs
[9] Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis, 2000; 4, 256-61. https://www.researchgate.net/publication/12565459_Slow_N-acetyltransferase_2_genotype_affects_the_incidence_of_isoniazid_and_rifampicin-induced_hepatotoxicity
[10] An HR, Wu XQ, Wang ZY, et al. NAT2 and CYP2E1 polymorphisms associated with antituberculosis drug-induced hepatotoxicity in Chinese patients. Clin Exp Pharmacol Physiol, 2012; 39, 535-43. doi:  10.1111/cep.2012.39.issue-6